Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Franklin Resources Inc.

Franklin Resources Inc. boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 398.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,497,764 shares of the medical equipment provider’s stock after acquiring an additional 2,796,372 shares during the quarter. Franklin Resources Inc. owned 1.76% of Zimmer Biomet worth $369,469,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Roman Butler Fullerton & Co. purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth about $473,000. Geode Capital Management LLC increased its stake in Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after buying an additional 125,852 shares in the last quarter. M&T Bank Corp raised its holdings in shares of Zimmer Biomet by 48.4% during the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock valued at $2,884,000 after acquiring an additional 8,709 shares during the last quarter. KLCM Advisors Inc. purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $7,825,000. Finally, Peddock Capital Advisors LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth approximately $654,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.95% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on ZBH. Barclays decreased their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. JMP Securities restated a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Truist Financial reiterated a “hold” rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $113.33 on Tuesday. The company has a market cap of $22.56 billion, a P/E ratio of 25.47, a P/E/G ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $131.61. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock has a 50-day moving average of $107.26 and a two-hundred day moving average of $107.10.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the company earned $2.20 earnings per share. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.85%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.